- Home
- FLGC vs SPRB Comparison
FLGC vs SPRB Comparison
Compare FLGC & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- SPRB
- Stock Information
- Founded
- FLGC 2019
- SPRB 2014
- Country
- FLGC United States
- SPRB United States
- Employees
- FLGC N/A
- SPRB N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- FLGC Health Care
- SPRB Health Care
- Exchange
- FLGC Nasdaq
- SPRB Nasdaq
- Market Cap
- FLGC 15.5M
- SPRB 15.7M
- IPO Year
- FLGC 2021
- SPRB 2020
- Fundamental
- Price
- FLGC $1.05
- SPRB $0.40
- Analyst Decision
- FLGC Strong Buy
- SPRB Hold
- Analyst Count
- FLGC 4
- SPRB 7
- Target Price
- FLGC $5.67
- SPRB $2.17
- AVG Volume (30 Days)
- FLGC 956.1K
- SPRB 885.3K
- Earning Date
- FLGC 11-13-2024
- SPRB 11-11-2024
- Dividend Yield
- FLGC N/A
- SPRB N/A
- EPS Growth
- FLGC N/A
- SPRB N/A
- EPS
- FLGC N/A
- SPRB N/A
- Revenue
- FLGC $64,154,000.00
- SPRB $7,101,000.00
- Revenue This Year
- FLGC N/A
- SPRB N/A
- Revenue Next Year
- FLGC $8.94
- SPRB N/A
- P/E Ratio
- FLGC N/A
- SPRB N/A
- Revenue Growth
- FLGC N/A
- SPRB N/A
- 52 Week Low
- FLGC $0.75
- SPRB $0.37
- 52 Week High
- FLGC $2.93
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- FLGC 36.74
- SPRB 36.54
- Support Level
- FLGC $1.60
- SPRB $0.37
- Resistance Level
- FLGC $1.22
- SPRB $0.42
- Average True Range (ATR)
- FLGC 0.20
- SPRB 0.04
- MACD
- FLGC -0.08
- SPRB -0.01
- Stochastic Oscillator
- FLGC 7.89
- SPRB 15.31
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).